Press Releases
At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Jun 18, 2015
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced the appointment of Michael...
-
Jun 16, 2015
Pulmatrix (Nasdaq: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced that it has entered into an ex-U.S....
- Jun 16, 2015PUR1900 is Lead Product Candidate in Company's Proprietary Pipeline Focused on Rare Pulmonary Diseases
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies for serious pulmonary diseases, today announced a new drug candidate, PUR1900, an...
- Jun 16, 2015Pulmatrix, Inc. now has $27 million in cash and cash equivalents
Pulmatrix, Inc., (NASDAQ: PULM), previously known as Ruthigen, Inc., today announced the completion of its previously announced merger, effective June 15, 2015, and the closing of a private...
-
Mar 16, 2015
Santa Rosa, Ca., March --- March 16, 2015 – Ruthigen, Inc. (NASDAQ: RTGN) (“Ruthigen”), and Pulmatrix, Inc., (“Pulmatrix”), a Lexington, Massachusetts based clinical stage...
-
May 5, 2014Results Demonstrated the Enablement of High Drug Load Delivery with iSPERSE Dry Powder Delivery Technology
Lexington, MA, May 5, 2014 – Pulmatrix today presented data at the 2014 Respiratory Drug Delivery Conference in Fajardo, Puerto Rico. The poster presentation includes development data on...
-
May 5, 2014Clinical Results Highlight Advantages of the iSPERSE Inhaled Dry Powder Delivery Platform over Conventional Lactose Blend Technologies
Lexington, MA, May 5, 2014 – Pulmatrix today announced the successful completion and positive results of the second part of a two-part Phase 1B clinical study in chronic obstructive...
